In short
A new clinical trial is investigating the use of Masofaniten (EPI-7386) in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC). This phase 1/2 study aims to evaluate the safety, tolerability, and effectiveness of this combination therapy compared to enzalutamide alone in patients who have not previously received second-generation anti-androgens. The trial will assess various aspects, including dose-limiting toxicities, maximum tolerated dose, and anti-tumor activity.
At a glance
- Study Type
- Phase 1/2 clinical trial
- Drugs Studied
- Masofaniten (EPI-7386) in combination with enzalutamide
- Condition
- Metastatic castration-resistant prostate cancer (mCRPC)
- Primary Objectives
- Evaluate safety, tolerability, and anti-tumor activity of the combination therapy
- Key Inclusion Criteria
- Males ≥18 years, confirmed mCRPC, naïve to second-generation anti-androgens
- Key Exclusion Criteria
- Significant cardiovascular disease, history of seizures, brain metastases
- Primary Endpoint (Phase 2)
- Proportion of subjects with PSA decline >90% (PSA90)
- Administration
- Oral use (film-coated tablet)
What is MASOFANITEN?
MASOFANITEN, also known as EPI-7386, is a new medication being studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is a small molecule drug that comes in the form of a film-coated tablet and is taken orally. MASOFANITEN is being developed by ESSA Pharmaceutical, Inc. and is currently undergoing clinical trials to evaluate its effectiveness and safety.
Medical Condition: Metastatic Castration-Resistant Prostate Cancer
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to hormone therapy (also known as androgen deprivation therapy or ADT). This condition occurs when prostate cancer cells continue to grow and spread despite low levels of testosterone in the body.
How MASOFANITEN Works
While the exact mechanism of action is not fully described in the provided information, MASOFANITEN is being studied in combination with another drug called enzalutamide. Both medications are considered anti-androgens, which means they work by blocking the effects of male hormones (androgens) on prostate cancer cells. This combination therapy aims to provide a more effective treatment for patients with mCRPC who have not previously been treated with second-generation anti-androgens.
Clinical Trial Details
The clinical trial for MASOFANITEN is a Phase 1/2 study that aims to evaluate the safety, tolerability, and effectiveness of EPI-7386 (MASOFANITEN) in combination with enzalutamide compared to enzalutamide alone. The study is divided into two phases:
Phase 1 Objectives:
- Determine the safety and tolerability of the combination therapy
- Establish the maximum tolerated dose (MTD) and/or recommended Phase 2 combination dose (RP2CD)
- Identify dose-limiting toxicities (DLTs)
- Evaluate the pharmacokinetics (how the drug moves through the body) of both MASOFANITEN and enzalutamide when used in combination
Phase 2 Objectives:
- Evaluate the anti-tumor activity of MASOFANITEN in combination with enzalutamide compared to enzalutamide alone
- Assess the safety of the combination therapy
- Further study the pharmacokinetics of both drugs in combination
Eligibility Criteria
To participate in this clinical trial, patients must meet specific criteria. Some key eligibility requirements include:
- Male patients aged 18 years or older
- Confirmed diagnosis of metastatic castration-resistant prostate cancer
- No prior treatment with second-generation anti-androgens
- Evidence of progressive disease despite ongoing androgen deprivation therapy
- Adequate organ function and performance status
There are also several exclusion criteria, such as certain cardiovascular conditions, brain metastases, or use of specific medications that may interfere with the study treatment.
Potential Benefits
While the effectiveness of MASOFANITEN is still being studied, the clinical trial aims to evaluate its potential benefits for patients with mCRPC. Some possible advantages of this treatment may include:
- Improved anti-tumor activity compared to current treatments
- A new option for patients who have not responded to other therapies
- Potential for better outcomes when combined with enzalutamide
Safety Considerations
As with any new medication, safety is a primary concern in the clinical trial of MASOFANITEN. The study will closely monitor patients for:
- Side effects and adverse events
- Changes in laboratory parameters, vital signs, and ECG readings
- Impact on overall performance status
It's important to note that potential risks and side effects will be thoroughly evaluated throughout the clinical trial process.
In conclusion, MASOFANITEN (EPI-7386) represents a promising new treatment option for patients with metastatic castration-resistant prostate cancer. As research continues, more information about its effectiveness and safety profile will become available, potentially offering hope to those affected by this challenging form of cancer.